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Palliative radiotherapy
Brain metastases, survival and recursive partitioning analysis (RPA) our experience
J. Pen˜a Vivas, C. Fuentes Sanchez, J. Martínez Cedres, S. Villamil Montufar, E. Garcia
Complejo Hospitalario Nuestra Sen˜ora de Candelaria-OFRA, Oncología Radioterápica
Brain metastases are common in cancer, lung it is the most frequent (40% of the total). The Radiationtherapy Oncology Group
Recursive PartitioningAnalysis (RPA) systemclassiﬁes the patients according to prognosis factors, (class I: Karnofsky performance
status>or = 70%, age<or = 65 years, no extracranial metastases, controlled primary tumor; class III: KPS<70%; class II: others).
Radiation therapy is the usual treatment.
Objective. To evaluate overall survival in patients with brain metastases treated with radiotherapy, according the primary tumor
and RPA class at a single institution.
Material and Methods. We retrospectively analyzed 206 patients with brain metastases diagnosed between January 2007 and
December 2011 treated with cranial RT (10×3 Gy) at our department.
Results. 150 patients (72.82%) lung cancer, 34 patients (16.5%) breast and 8 patients (3.88%) colorectal. 134 males (65.05%) and 72
women (34.95%). RPA: class 1, 42 patients (20.39%), class 2, 137 patients (66.5%) and class 3 27 patients (13.11%). The mean overall
survival was 10.73 months (0.1 to 84 months, median 6 months). According to the primary tumor and RPA, mean survivals were:
lung class 1, 9.6 months (median 6 months), class 2: 9.18 months (median 6 months) and class 3, 3.34 months (median 2 months).
Breast, class 1: 20.25 months (median 18.5), class 2: 17.12 months (median 9 months) and class 3: 15.6 months (median 5 months).
In lung cancer the mean of survival was signiﬁcantly higher among male vs. female 7.35 months vs 12.29 months, p=0.0053.
Conclusions. Only class 1 and 2 and breast cancer seem to have clear beneﬁt with radiotherapy. There was no difference in survival
between groups 1 and 2. Despite the use of RT holocraneal, the results are poor and efforts must be made to incorporate the
multimodality therapies in patients with more favorable RPA class 1 and 2.
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Early deaths in radiation oncology
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Introduction. On 2011, at the Hospital Universitario Donostia we evaluated 1206 patients. 192 died that year but we realized that
42 patients died early, dying before than 30 days since we decided the patient should be treated with radiotherapy.
Objectives. We analyzed the characteristics of these patients and if there was any new criteria or feature that we did not take into
account so we can be more careful for the future patients and avoid the unnecessary treatments.
Material and methods. We studied the features of the 1206 patients evaluated on 2011 and looked in more detail the 42 clinical
histories of the ones that died early. Statistical analysis was done with the software SPSS 20.0
Results. We found that there was a quite high heterogeneity in those patients. We divided patients characteristics between
Karnofsky Status (≤70%, >70%), number of cerebral metastases (≤3, >3), radiotherapy ﬁnalized or not, overall survival (days),
histology, primary tumor, concomitant chemotherapy treatment or not, treatment started before or after 3 days, irradiated zone,
age and cause of death. We appreciate that most of them had a low Karnofsky Status and more than 3 metastases, features
that we already know are signs of a poor prognosis but the rest of the characteristics we looked were not ﬁnally statistically
signiﬁcant. So we did not ﬁnd any new trait that could help us to asses the patient and the family when can we avoid a palliative
intention treatment because it is highly probable that is going to die in less than 30 days.
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